
DNA • NYSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold DNA in your mock portfolio yet.
The company is currently unprofitable, as reflected in its negative EPS and negative P/E ratio. This implies that, despite any growth initiatives, Ginkgo Bioworks has yet to demonstrate a clear path to sustainable earnings. Without visible improvement in profitability metrics, the financial profile remains high risk.
The stock has risen 9.3% over the last month and trades just below its 200-day moving average, suggesting it is near a key long-term technical level. However, the very low RSI of 21.07 signals the shares are in oversold territory, which can either precede a short-term bounce or reflect persistent selling pressure. Overall, technicals are mixed, with some near-term rebound potential but no clear long-term uptrend confirmed.
Alternative data show modest signs of operational and brand activity but not strong momentum. Job openings have increased sharply month over month, hinting at some expansion or renewed investment in growth, while LinkedIn and Twitter/X followers are growing slowly, suggesting steady but not explosive interest. However, overall web traffic appears low for a public company, and social media growth is uneven across platforms.
Overall, the stock’s fundamental profile is constrained by ongoing losses and negative earnings, leaving the story heavily dependent on future execution rather than current profitability. Technicals suggest possible short-term trading opportunities due to oversold conditions, but they do not yet confirm a durable positive trend. Alternative data show modest engagement and some hiring growth, but not enough to offset the underlying financial risk profile.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: